openPR Logo
Press release

Investigation announced for Investors who lost money with shares of Siemens Aktiengesellschaft (OTC: MNEY, OTC: SMEGF)

09-11-2023 08:09 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation for investors in Siemens Aktiengesellschaft (OTC: MNEY, OTC: SMEGF) shares.

An investigation for investors in Siemens Aktiengesellschaft (OTC: MNEY, OTC: SMEGF) shares.

An investigation was announced over potential securities laws violations by Siemens Aktiengesellschaft in connection with certain financial statements.

Investors who purchased shares of Siemens Aktiengesellschaft (OTC: MNEY, OTC: SMEGF), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Siemens Aktiengesellschaft (OTC: MNEY, OTC: SMEGF) concerning whether a series of statements by Siemens Aktiengesellschaft regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On June 22, 2023, after the market closed, Siemens Aktiengesellschaft disclosed that it had found a "substantial increase in failure rates of wind turbine components" and had initiated an "extended technical review," which would cost approximately 1 billion euros. Furthermore, Siemens Aktiengesellschaft withdrew its profit guidance for fiscal year 2023.

Then, on June 23, 2023, the Company's CEO told journalists that "too much had been swept under the carpet" and that the quality issues were "more severe than [he] thought possible."

Shares of Siemens Aktiengesellschaft (OTC: SMNEY, OTC: SMEGF) declined from $26.23 per OTC: SMNEY share on May 19, 2023 to $12.98 per OTC: SMNEY share on Septbemter 08, 2023, respectively from $26.37 per OTC: SMEGF share on May 22, 2023, to $12.78 per OTC: SMEGF share on September 07, 2023.

Those who purchased shares of Siemens Aktiengesellschaft (OTC: MNEY, OTC: SMEGF) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors who lost money with shares of Siemens Aktiengesellschaft (OTC: MNEY, OTC: SMEGF) here

News-ID: 3204055 • Views:

More Releases from Shareholders Foundation

Lawsuit filed for Investors who lost money with shares of The Scotts Miracle-Gro Company (NYSE: SMG)
Lawsuit filed for Investors who lost money with shares of The Scotts Miracle-Gro …
An investor, who purchased shares of The Scotts Miracle-Gro Company (NYSE: SMG), filed a lawsuit over alleged violations of Federal Securities Laws by The Scotts Miracle-Gro Company in connection with certain allegedly false and misleading statements. Investors who purchased shares of The Scotts Miracle-Gro Company (NYSE: SMG) have certain options and for certain investors are short and strict deadlines running. Deadline: August 5, 2024. NYSE: SMG investors should contact the Shareholders
Investigation announced for Long-Term Investors in Cidara Therapeutics, Inc. (NASDAQ: CDTX) over potential Wrongdoing
Investigation announced for Long-Term Investors in Cidara Therapeutics, Inc. (NA …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Cidara Therapeutics, Inc. Investors who purchased shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Cidara Therapeutics, Inc. (directors breached their fiduciary duties and caused damage to the company and its shareholders. San
Lawsuit filed for Investors in Charge Enterprises, Inc. (formerly NASDAQ: CRGE) in effort to recover losses
Lawsuit filed for Investors in Charge Enterprises, Inc. (formerly NASDAQ: CRGE) …
An investor, who purchased shares of Charge Enterprises, Inc. (formerly NASDAQ: CRGE), filed a lawsuit over alleged violations of Federal Securities Laws by the former CEO and CFO of Charge Enterprises, Inc in connection with certain allegedly false and misleading statements made between December 15, 2021 and February 28, 2024. Investors who purchased shares of Charge Enterprises, Inc. (formerly NASDAQ: CRGE) between December 15, 2021 and February 28, 2024, and continue
Deadline on June 10th coming up in Lawsuit for Investors in shares of Ocugen, Inc. (NASDAQ: OCGN)
Deadline on June 10th coming up in Lawsuit for Investors in shares of Ocugen, In …
A deadline is coming up on June 10, 2024 in the lawsuit filed for certain investors of Ocugen, Inc. (NASDAQ: OCGN) over alleged securities laws violations by Ocugen, Inc. Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN ) have certain options and there are strict and short deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to

All 5 Releases


More Releases for OTC:

Deadline on Nov. 9th upcoming in Lawsuit for Investors in Harborside Inc. (OTC: …
The Shareholders Foundation announced that a deadline is coming up on November 9, 2020 in the lawsuit filed for certain investors of Harborside Inc. (OTC: HSDEF, OTC: HBORF). Investors who purchased shares of Harborside Inc. (OTC: HSDEF, OTC: HBORF) have certain options and there are strict and short deadlines running. Deadline: November 9, 2020. Harborside Inc. stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to
Investigation for Long-Term Investors in shares of Volkswagen AG (OTC: VWAGY / O …
An investigation on behalf of current long-term investors in shares of Volkswagen AG (OTC: VWAGY / OTC: VLKAF / OTC: VWAPY) was announced over potential breaches of fiduciary duties by certain officers and directors at Volkswagen AG. Investors who purchased shares of Volkswagen AG (OTC: VWAGY / OTC: VLKAF / OTC: VWAPY) and currently hold any of those Volkswagen AG shares have certain options and should contact the Shareholders Foundation at
OTC: VWAGY / OTC: VLKAF / OTC: VWAPY Shareholder Notice: Update in Lawsuit again …
The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Volkswagen AG (OTC: VWAGY) (OTC: VWAPY) shares. Investors, who purchased shares of Volkswagen AG (OTC: VWAGY) (OTC: VLKAF) (OTC: VWAPY), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. On September 25, 2015, a lawsuit was filed against Volkswagen AG (alleged securities laws violations. The plaintiff claimed that the defendants
OTC Analgesics Market OTC analgesics market is projected to register a steady ex …
About OTC Analgesics Market The global OTC analgesics market is projected to register an above-average CAGR during 2017 to 2022. Global sales of OTC analgesics is estimated to account for nearly US$ 25,000 Mn revenues by 2022-end. Get Sample copy of this Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=75 The trend of using off-label drugs that are affordable and unapproved, but effective in treating diseases, has been witnessing an upsurge over the past few years.
03-14-2018 | Health & Medicine
Fact.MR
OTC Analgesics Market Report 2017-22: Pharmacy to Remain the Most Lucrative OTC …
A fresh study, covering “OTC Analgesics Market Forecast, Trend Analysis & Competition Tracking – Global Review 2017 to 2022” has been broadcasted to wide online repository of Fact MR, which presents deep focus on the healthcare market. This smart study contains precise data that offers a clear insight about market current scenario and future projections for the benefit of readers. Moreover, the study enclosed significant data which tends to make
The OTC Drugs Market: Commercial Trends and Rx-to-OTC Switch Prospects
ReportsWeb.com has announced the addition of the “Global OTC Drugs Market Research Report 2017” The report focuses on global major leading industry players with information such as company profiles, product picture and specification. GBI Research's latest report, "The OTC Drugs Market: Commercial Trends and Rx-to-OTC Switch Prospects" discusses trends in the over-the-counter (OTC) pharmaceuticals market and the commercial prospects for switching drugs from prescription-only to OTC status. The report assesses current